351 related articles for article (PubMed ID: 36271374)
1. Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Yang TK; Yu YF; Tsai CL; Li HJ; Yang PS; Huang KW; Cheng JC
BMC Cancer; 2022 Oct; 22(1):1085. PubMed ID: 36271374
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S
BMC Cancer; 2023 May; 23(1):474. PubMed ID: 37226111
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
Feng J; Zhao Y; Zhai L; Zhou J
Medicine (Baltimore); 2024 May; 103(18):e38037. PubMed ID: 38701263
[TBL] [Abstract][Full Text] [Related]
5. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
6. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
Pinato DJ; Marron TU; Mishra-Kalyani PS; Gong Y; Wei G; Szafron D; Sharon E; Saeed A; Jun T; Dharmapuri S; Naqash AR; Peeraphatdit T; Gampa A; Wang Y; Khan U; Muzaffar M; Navaid M; Lee CJ; Lee PC; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Hildebrand H; Abugabal YI; Pressiani T; Personeni N; D'Alessio A; Kaseb AO; Huang YH; Ang C; Schneider J; Pillai A; Rimassa L; Goldberg KB; Pazdur R; Theoret M; Lemery S; Fashoyin-Aje '; Cortellini A; Pelosof L
Eur J Cancer; 2021 Nov; 157():140-152. PubMed ID: 34508996
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
Liu K; Zhu Y; Zhu H
Front Immunol; 2022; 13():1103055. PubMed ID: 36713376
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis.
Xian F; Wu C; Zhang G; Xu G
Medicine (Baltimore); 2022 Nov; 101(44):e31479. PubMed ID: 36343054
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis.
Lei Q; Yan X; Zou H; Jiang Y; Lai Y; Ung COL; Hu H
Discov Oncol; 2022 Sep; 13(1):95. PubMed ID: 36171533
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for metastatic renal cell carcinoma.
Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
[TBL] [Abstract][Full Text] [Related]
15. Comparing the clinical efficacy and safety of second-line targeted therapy and immunotherapy in patients with mid- to advanced stages of hepatocellular carcinoma - A systematic review and meta-analysis of randomized clinical trials.
Li JF; Fu YX; Zhang HC; Ma H; Yuan GJ; Tan Y
Eur Rev Med Pharmacol Sci; 2023 Nov; 27(22):11156-11168. PubMed ID: 38039047
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
18. Adverse Events of Immune Checkpoint Inhibitor-Based Therapies for Unresectable Hepatocellular Carcinoma in Prospective Clinical Trials: A Systematic Review and Meta-Analysis.
Zhang Y; Wang M; Chen Q; Deng Y; Chen J; Dai Y; Luo S; Xu J; Zhao H; Cai J
Liver Cancer; 2023 Dec; 12(6):521-538. PubMed ID: 38476294
[TBL] [Abstract][Full Text] [Related]
19. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Rao Q; Li M; Xu W; Pang K; Guo X; Wang D; Liu J; Guo W; Zhang Z
Hepatol Int; 2020 Sep; 14(5):765-775. PubMed ID: 32572818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]